HighGravityDataCurrent guidance
42 items
BioMarin Pharmaceutical
Guidance from BioMarin Pharmaceutical’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Aug 6, 2026
Data checked
Aug 6, 2026
What changed in the Aug 6, 2026 release
Each item compared with the same item in the previous release (May 4, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| New | Peak revenue for GALAFOLD | for FY2030 | — | “approximately $1.4 billion” | Filing ↗ |
| New | Peak revenue for POMBILITI + OPFOLDA | for FY2030 | — | “approximately $1.2 billion” | Filing ↗ |
| New | Metabolic Conditions Revenue | for FY2026 | — | “Unchanged” | Filing ↗ |
| Narrowed | Total Revenues | for FY2026 | “$3,825 to $3,925” | “$3,875 to $3,925” | Filing ↗ |
| New | Total Revenues Midpoint Growth (Y/Y) | for FY2026 | — | “21%” | Filing ↗ |
| New | VOXZOGO full-year 2026 revenue (CEO quote) | for FY2026 | — | “at least $1 billion” | Filing ↗ |
| New | VOXZOGO Revenue | for FY2026 | — | “$1,000 to $1,050” | Filing ↗ |
| New | GALAFOLD and POMBILITI + OPFOLDA, combined, Non-GAAP Operating Margin | for FY2030 | — | “over 60%” | Filing ↗ |
| New | Combined company tax rate assumption for Non-GAAP Diluted EPS | for FY2026 | — | “22%” | Filing ↗ |
| Raised | Non-GAAP Diluted EPS | for FY2026 | “$4.85 to $5.05” | “$4.90 to $5.10” | Filing ↗ |
| New | Non-GAAP Diluted EPS Midpoint Growth (Y/Y) | for FY2026 | — | “59%” | Filing ↗ |
| New | Weighted-Average Diluted Shares Outstanding assumption for Non-GAAP Diluted EPS | for FY2026 | — | “approximately 200 million” | Filing ↗ |
| New | Cost reductions from Amicus acquisition (GAAP basis) | for FY2028 | — | “approximately $280 million” | Filing ↗ |
| New | Cost reductions from Amicus acquisition (Non-GAAP basis) | for FY2028 | — | “approximately $220 million” | Filing ↗ |
| New | Cost reductions on a GAAP basis | for FY2028 | — | “approximately $280 million” | Filing ↗ |
| New | Gross leverage target | for FY2027 | — | “below 2.5 times” | Filing ↗ |
| New | Metabolic Conditions | for FY2026 | — | “$2,725 to $2,775” | Filing ↗ |
| New | Metabolic Conditions Midpoint Growth (Y/Y) | for FY2026 | — | “31%” | Filing ↗ |
| New | VOXZOGO Midpoint Growth (Y/Y) | for FY2026 | — | “11%” | Filing ↗ |
| Reiterated | Other Revenues | for FY2026 | “$100 to $125” | “$100 to $125” | Filing ↗ |
Show 10 items not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Total revenues CAGR | for FY2034 | “Mid-teen compound annual growth rate (CAGR)” | — | Filing ↗ |
| Not restated | Total revenues compound annual growth rate (CAGR) | for FY2034 | “Mid-teen” | — | Filing ↗ |
| Not restated | PALYNZIQ Revenue | for FY2026 | “expected to increase year-over-year” | — | Filing ↗ |
| Not restated | Total Revenues (Full-Year) | for FY2026 | “between $3.825 billion and $3.925 billion” | — | Filing ↗ |
| Not restated | Treatments for Skeletal Conditions revenue opportunity | No period stated | “greater than $5 billion” | — | Filing ↗ |
| Not restated | Amicus Acquisition Impact on Non-GAAP Diluted EPS | for FY2026 | “slightly dilutive” | — | Filing ↗ |
| Not restated | Non-GAAP Diluted EPS Recognized in Second Half of 2026 | for H2 FY2026 | “approximately two-thirds” | — | Filing ↗ |
| Not restated | Non-GAAP Operating Margin | for FY2026 | “40%” | — | Filing ↗ |
| Not restated | Non-GAAP Operating Margin | No period stated | “low- to mid-40% range” | — | Filing ↗ |
| Not restated | Enzyme Therapies long-term growth outlook (CAGR) | for the long term | “high single-digit CAGR” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Metabolic Conditions Revenue | “Unchanged” | for FY2026 | GAAP-tied | Aug 6, 2026 | 1 | Filing ↗ |
| Other Revenues | “$100 to $125” | for FY2026 | GAAP-tied | May 4, 2026 | 2 | Filing ↗ |
| PALYNZIQ Revenue | “expected to increase year-over-year” | for FY2026 | GAAP-tied | May 4, 2026 | 1 | Filing ↗ |
| ROCTAVIAN revenue treatment in 2026 | “ROCTAVIAN revenue to be excluded from 2026 guidance” | for FY2026 | GAAP-tied | Jan 12, 2026 | 1 | Filing ↗ |
| Total Revenues | “$3,875 to $3,925” | for FY2026 | GAAP-tied | May 4, 2026 | 2 | Filing ↗ |
| Total Revenues (Full-Year) | “between $3.825 billion and $3.925 billion” | for FY2026 | GAAP-tied | May 4, 2026 | 1 | Filing ↗ |
| Total Revenues Expected in Second Half of 2026 | “more than 55%” | for H2 FY2026 | GAAP-tied | May 4, 2026 | 1 | Filing ↗ |
| Total Revenues Growth Rate (Y/Y, at Midpoint) | “20%” | for FY2026 | GAAP-tied | May 4, 2026 | 1 | Filing ↗ |
| Total Revenues Midpoint Growth (Y/Y) | “21%” | for FY2026 | GAAP-tied | Aug 6, 2026 | 1 | Filing ↗ |
| VOXZOGO full-year 2026 revenue (CEO quote) | “at least $1 billion” | for FY2026 | GAAP-tied | Aug 6, 2026 | 1 | Filing ↗ |
| VOXZOGO Revenue | “$1,000 to $1,050” | for FY2026 | GAAP-tied | Aug 6, 2026 | 1 | Filing ↗ |
| Amicus Acquisition Impact on Non-GAAP Diluted EPS | “slightly dilutive” | for FY2026 | Company-defined | May 4, 2026 | 1 | Filing ↗ |
| Combined company tax rate assumption for Non-GAAP Diluted EPS | “22%” | for FY2026 | Company-defined | Aug 6, 2026 | 1 | Filing ↗ |
| Non-GAAP Diluted EPS | “$4.90 to $5.10” | for FY2026 | Company-defined | May 4, 2026 | 2 | Filing ↗ |
| Non-GAAP Diluted EPS - combined company tax rate assumption | “22%” | for FY2026 | Company-defined | May 4, 2026 | 1 | Filing ↗ |
| Non-GAAP Diluted EPS - Weighted-Average Diluted Shares Outstanding assumption | “approximately 200 million” | for FY2026 | Company-defined | May 4, 2026 | 1 | Filing ↗ |
| Non-GAAP Diluted EPS Midpoint Growth (Y/Y) | “59%” | for FY2026 | Company-defined | Aug 6, 2026 | 1 | Filing ↗ |
| Non-GAAP Diluted EPS Recognized in Second Half of 2026 | “approximately two-thirds” | for H2 FY2026 | Company-defined | May 4, 2026 | 1 | Filing ↗ |
| Non-GAAP Operating Margin | “40%” | for FY2026 | Company-defined | Oct 29, 2024 | 2 | Filing ↗ |
| Weighted-Average Diluted Shares Outstanding assumption for Non-GAAP Diluted EPS | “approximately 200 million” | for FY2026 | Company-defined | Aug 6, 2026 | 1 | Filing ↗ |
| Enzyme Therapies | “$2,725 to $2,775” | for FY2026 | Company-defined | May 4, 2026 | 1 | Filing ↗ |
| Metabolic Conditions | “$2,725 to $2,775” | for FY2026 | Company-defined | Aug 6, 2026 | 1 | Filing ↗ |
| Metabolic Conditions Midpoint Growth (Y/Y) | “31%” | for FY2026 | Company-defined | Aug 6, 2026 | 1 | Filing ↗ |
| VOXZOGO | “$975 to $1,025” | for FY2026 | Company-defined | May 4, 2026 | 1 | Filing ↗ |
| VOXZOGO Midpoint Growth (Y/Y) | “11%” | for FY2026 | Company-defined | Aug 6, 2026 | 1 | Filing ↗ |
Next year and medium term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Total revenues CAGR | “Mid-teen compound annual growth rate (CAGR)” | for FY2034 | GAAP-tied | Oct 29, 2024 | 1 | Filing ↗ |
| Total revenues compound annual growth rate (CAGR) | “Mid-teen” | for FY2034 | GAAP-tied | Oct 29, 2024 | 1 | Filing ↗ |
| Peak revenue for GALAFOLD | “approximately $1.4 billion” | for FY2030 | GAAP-tied | Aug 6, 2026 | 1 | Filing ↗ |
| Peak revenue for POMBILITI + OPFOLDA | “approximately $1.2 billion” | for FY2030 | GAAP-tied | Aug 6, 2026 | 1 | Filing ↗ |
| Total Revenues | “approximately $4 billion” | for FY2027 | GAAP-tied | Oct 29, 2024 | 2 | Filing ↗ |
| GALAFOLD and POMBILITI + OPFOLDA, combined, Non-GAAP Operating Margin | “over 60%” | for FY2030 | Company-defined | Aug 6, 2026 | 1 | Filing ↗ |
| BMN 333 achondroplasia approval target | “2030” | for FY2030 | Company-defined | May 1, 2025 | 1 | Filing ↗ |
| Cost reductions from Amicus acquisition (GAAP basis) | “approximately $280 million” | for FY2028 | Company-defined | Aug 6, 2026 | 1 | Filing ↗ |
| Cost reductions from Amicus acquisition (Non-GAAP basis) | “approximately $220 million” | for FY2028 | Company-defined | Aug 6, 2026 | 1 | Filing ↗ |
| Cost reductions on a GAAP basis | “approximately $280 million” | for FY2028 | Company-defined | Aug 6, 2026 | 1 | Filing ↗ |
| Gross leverage target | “below 2.5 times” | for FY2027 | Company-defined | Aug 6, 2026 | 1 | Filing ↗ |
| Operating cash flow | “More than $1.25 billion” | for FY2027 | GAAP-tied | Oct 29, 2024 | 1 | Filing ↗ |
| Operating cash flows | “more than $1.25 billion” | for FY2027 | GAAP-tied | Feb 19, 2025 | 1 | Filing ↗ |
| VOXZOGO country access expansion | “more than 20 additional countries” | for FY2027 | Company-defined | Oct 29, 2024 | 1 | Filing ↗ |
| VOXZOGO country access target | “more than 60 countries” | for FY2027 | Company-defined | Aug 4, 2025 | 1 | Filing ↗ |
| VOXZOGO country availability | “more than 60 countries” | for FY2027 | Company-defined | Feb 19, 2025 | 1 | Filing ↗ |
Long term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Enzyme Therapies long-term growth outlook (CAGR) | “high single-digit CAGR” | for the long term | Company-defined | Feb 19, 2025 | 1 | Filing ↗ |
How one item moved
Total Revenues, for FY2026 — every statement across the year, each linked to its filing.
How your Biopharma sector group guides
12 companies in Biopharma. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| BioMarin Pharmaceutical | Aug 6, 2026 | 19 changes |
| Halozyme Therapeutics | Aug 6, 2026 | 6 changes |
| Eli Lilly | Aug 5, 2026 | 5 changes |
| Amgen | Aug 4, 2026 | 5 changes |
| Gilead Sciences | Aug 4, 2026 | 15 changes |
| Moderna | Jul 31, 2026 | 8 changes |
| Neurocrine Biosciences | Jul 30, 2026 | 16 changes |
| Regeneron Pharmaceuticals | Jul 30, 2026 | 22 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2034 | FY2030 | FY2028 | FY2027 | FY2026 | FY2025 | FY2024 | FY2023 | Long-term | No period |
|---|---|---|---|---|---|---|---|---|---|---|
| Metabolic Conditions Revenue | — | — | — | — | 1 statement | — | — | — | — | — |
| Other Revenues | — | — | — | — | 2 statements | — | — | — | — | — |
| PALYNZIQ Revenue | — | — | — | — | 1 statement | — | — | — | — | — |
| Peak revenue for GALAFOLD | — | 1 statement | — | — | — | — | — | — | — | — |
| Peak revenue for POMBILITI + OPFOLDA | — | 1 statement | — | — | — | — | — | — | — | — |
The full record for BioMarin Pharmaceutical and its Biopharma peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Aug 6, 2026 | FY2026 Q2 | 0001048477-26-000015 | 22 | Open filing ↗ |
| May 4, 2026 | FY2026 Q1 | 0001048477-26-000006 | 14 | Open filing ↗ |
| Jan 12, 2026 | FY2025 Q4 | 0001193125-26-010508 | 8 | Open filing ↗ |
| Oct 7, 2025 | FY2025 Q3 | 0001048477-25-000101 | 3 | Open filing ↗ |
| Aug 4, 2025 | FY2025 Q2 | 0001048477-25-000088 | 9 | Open filing ↗ |
| May 1, 2025 | FY2025 Q1 | 0001048477-25-000049 | 6 | Open filing ↗ |
| Feb 19, 2025 | FY2024 Q4 | 0001048477-25-000004 | 14 | Open filing ↗ |
| Oct 29, 2024 | FY2024 Q3 | 0001048477-24-000149 | 12 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error